Indene

Indene

SCHEMBL2967405

C1=Cc2ccccc2C1.[C]

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
PARP1 P09874 1/20 0.41
TSHR P16473 1/20 0.33
MAOB P27338 2/20 0.31
TRPA1 O75762 1/20 0.31
IDO1 P14902 2/20 0.31
CYP1A2 P05177 1/20 0.31
KDM4E B2RXH2 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indene SCHEMBL29350094 0.97
Indene SCHEMBL8617 0.97
Indene SCHEMBL8336138 0.97 CA1 (0.55) CA1CA2CYP2D6CYP2C19PARP1
Indene SCHEMBL7153004 0.95 CA1 (0.53) CA1CA2CYP2D6CYP2C19PARP1
Indene SCHEMBL8971559 0.95 CA1 (0.53) CA1CA2CYP2D6CYP2C19PARP1
Indene SCHEMBL23071394 0.95 CA1 (0.53) CA1CA2CYP2D6CYP2C19PARP1
Indene SCHEMBL1054910 0.95 CA1 (0.53) CA1CA2CYP2D6CYP2C19PARP1
Indene SCHEMBL8971580 0.95 CA1 (0.53) CA1CA2CYP2D6CYP2C19PARP1
Indene SCHEMBL23301011 0.95 CA1 (0.53) CA1CA2CYP2D6CYP2C19PARP1
Indene SCHEMBL6285027 0.95 CA1 (0.53) CA1CA2CYP2D6CYP2C19PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136675-A Euphorbia lathyris spiro diterpenoid compound, preparation method thereof and application thereof in preventing and controlling plant fungal diseases 江苏省中国科学院植物研究所 2025-06-13 CN disclosed
CN-120025253-A Compounds useful as active compounds in organic electronic devices 默克专利有限公司 2025-05-23 CN disclosed
CN-111479811-B Heterocyclic compounds for electronic devices 默克专利有限公司 2025-05-16 CN disclosed
CN-112739795-B Compounds useful as active compounds in organic electronic devices 默克专利有限公司 2025-02-21 CN disclosed
US-12035625-B2 Materials for organic electroluminescent devices MERCK PATENT GMBH (DE) 2024-07-09 US disclosed
CN-112384595-B Material for organic electroluminescent device 默克专利有限公司 2024-05-28 CN disclosed
CN-113195500-B Material for organic electroluminescent device 默克专利有限公司 2024-05-17 CN disclosed
EP-3548481-B1 HETEROCYCLIC COMPOUNDS FOR USE IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2023-08-23 EP disclosed
EP-3548467-B1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES MERCK PATENT GMBH (DE) 2023-06-21 EP disclosed
EP-3880682-B1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2023-06-14 EP disclosed
WO-2002014536-A9 ODULATING MULTIPLE LINEAGE KINASE PROTEINS CEPHALON INC (US) 2003-12-18 WO disclosed
EP-1309721-A2 MODULATING MULTIPLE LINEAGE KINASE PROTEINS CEPHALON, INC. (US) 2003-05-14 EP disclosed
US-6359130-B1 ANTIBIOTIC, ANTITUMOR AGENT, ANTIINFLAMMATORY AGENT CEPHALON, INC. 2002-03-19 US disclosed
WO-2002014536-A2 ODULATING MULTIPLE LINEAGE KINASE PROTEINS CEPHALON, INC. (US) 2002-02-21 WO disclosed
EP-1083903-A4 BRIDGED INDENOPYRROLOCARBAZOLES CEPHALON INC (US) 2001-10-04 EP disclosed
EP-1105728-A1 MODULATING MULTIPLE LINEAGE KINASE PROTEINS CEPHALON, INC. (US) 2001-06-13 EP disclosed
EP-1083903-A1 BRIDGED INDENOPYRROLOCARBAZOLES CEPHALON, INC. (US) 2001-03-21 EP disclosed
US-6127401-A TREATMENT OF PROSTATE DISORDERS, ANGIOGENIC DISORDERS, NEOPLASIA, RHEUMATOID ARTHRITIS, PULMONARY FIBROSIS, MYELOFIBROSIS, ABNORMAL WOUND HEALING, ATHEROSCLEROSIS, OR RESTENOSIS, ALZHEIMER'S DISEASE CEPHALON, INC. (US) 2000-10-03 US disclosed
WO-2000013015-A1 MODULATING MULTIPLE LINEAGE KINASE PROTEINS CEPHALON, INC. (US) 2000-03-09 WO disclosed
WO-1999062523-A1 BRIDGED INDENOPYRROLOCARBAZOLES CEPHALON, INC. (US) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12035625-B2 Materials for organic electroluminescent devices ZYX, RER1, AOC2 CA1 668/4885CA2 882/4885CYP2D6 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.